Genomic Health Gets KO'd By Next-Gen Long-Term Breast Cancer Assays

The new-generation of tests from Myriad and NanoString have outperformed Genomic Health's Oncotype Dx in predicting which breast cancer patients are at low-risk for a recurrence in five to ten years, and therefore do not need to be on extended endocrine therapy.

Results from the TransATAC trial show that Myriad Genetics Inc.'s EndoPredict and NanoString Technologies Inc.'s Prosigna second-generation tests are superior to Genomic Health Inc.'s Oncotype Dx first-generation test for predicting the long-term recurrence of breast cancer.

TransATAC “answers a critically important unmet need/question, which is how to we best manage patients with breast cancer after they've...

More from Clinical Trials

More from R&D

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By 

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.